학술논문
Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588).
Document Type
Article
Author
Source
Subject
*OVARIAN cancer
*CANCER patients
*IMMUNOGLOBULINS
*DRUGS
*
*
*
Language
ISSN
0090-8258